WEBULL
WebtradeDownload

Astrana Health (ASTH) Stock May Be Fully Priced As Shares Fell 67%

Simply Wall St · 1d ago

Astrana Health has had a mixed share price journey, with a long stretch that has been difficult for holders and a more recent recovery. That uneven track record puts attention squarely on what the current US$33.55 price says about the company’s earnings power today.

  • The stock has fallen 66.6% over the past 5 years. This puts real pressure on the question of whether the current valuation is now more closely aligned with Astrana Health’s earnings profile.
  • As a physician enablement and care management specialist, the business model leans heavily on how efficiently it can convert managed care contracts into sustainable profit margins. This can influence how much investors are willing to pay for each dollar of earnings.
  • Your read on Astrana Health is one view; the desks covering it have another. See what analysts think Astrana Health's shares could be worth.

The issue now is whether Astrana Health’s recent share price level is adequately supported by the earnings the business is currently generating and is expected to produce.

If you want to cross check Astrana Health’s earnings driven valuation against a wider field, compare it with 30 high quality undervalued stocks.

Has Astrana Health Run Too Far on Earnings?

The P/E ratio fits Astrana Health because earnings matter a lot for a service heavy healthcare platform. At the current share price, the stock trades on a P/E of about 42.3x, compared with a Healthcare industry average of roughly 24.0x and a peer group around 48.3x. That puts Astrana Health at a clear premium to the broader sector while still sitting below the narrower peer set.

The fair value model suggests a lower P/E would better match Astrana Health’s earnings quality and risk profile, so the current 42.3x reading points to the shares looking overvalued on this metric. For anyone assessing the ticker, the key question is whether the company’s execution in physician enablement and care management justifies paying this richer multiple relative to what the model views as a more balanced level. Explore the numbers behind Astrana Health's P/E valuation.

NasdaqCM:ASTH P/E Ratio as at Sep 2026
NasdaqCM:ASTH P/E Ratio as at Sep 2026

The Astrana Health Narrative: What Would Justify Today's Price?

Narratives for Astrana Health pick up where the P/E debate leaves off by spelling out which future paths for growth, margins and earnings would make the current share price look either stretched or conservative, using the Community page as their home. Instead of a single ratio or model output, they map the future performance that number quietly assumes, so you can watch whether those conditions actually play out over time.

One of the top community narratives on Astrana Health: 33% undervalued

"Astrana's acquisition and successful early integration of Prospect Health are creating potential for significant operational synergies, broader scale, and increased bargaining power with payers..."

Discover why this Narrative puts Astrana Health at 33% undervalued.

One more Astrana Health check that belongs beside the current share price

Price ratios tell you what the market pays for Astrana Health today, while professional projections sketch where earnings and cash flows might be a few years out and how that lines up with this valuation. Explore where analysts expect Astrana Health to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.